See more : Jhu Jian Catering Co., Ltd. (7723.TWO) Income Statement Analysis – Financial Results
Complete financial analysis of BioElectronics Corporation (BIEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioElectronics Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- S.A.S. Dragon Holdings Limited (1184.HK) Income Statement Analysis – Financial Results
- Smooth Rock Ventures Corp. (SMRVF) Income Statement Analysis – Financial Results
- Neutra Corp. (NTRR) Income Statement Analysis – Financial Results
- Spartan Delta Corp. (SDE.TO) Income Statement Analysis – Financial Results
- Pyramid Technoplast Limited (PYRAMID.NS) Income Statement Analysis – Financial Results
BioElectronics Corporation (BIEL)
About BioElectronics Corporation
BioElectronics Corporation, an electroceutical company, engages in the development and sale of wearable, neuromodulation devices to mitigate neurological diseases and enhance quality of life worldwide. Its products include ActiPatch, a musculoskeletal pain therapy; Allay, a menstrual pain therapy; and Smart Insole, a heel pain therapy. The company also offers RecoveryRx, a medical device that provides pain management therapy for medical professionals; and HealFast, a drug-free therapy for horses, cats, and dogs that reduces swelling and pain, as well as heals muscle and tendon injuries, sores, and incisions. It sells its products to wholesale distributors, hospitals and clinics, and consumers. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 714.71K | 707.41K | 1.61M | 829.56K | 941.76K | 1.05M | 1.76M | 2.09M | 2.34M | 1.29M | 665.51K |
| Cost of Revenue | 248.32K | 220.90K | 813.93K | 323.39K | 412.90K | 690.68K | 767.92K | 834.24K | 1.01M | 744.82K | 430.72K |
| Gross Profit | 466.39K | 486.52K | 795.53K | 506.17K | 528.86K | 355.19K | 995.84K | 1.26M | 1.33M | 545.08K | 234.79K |
| Gross Profit Ratio | 65.26% | 68.77% | 49.43% | 61.02% | 56.16% | 33.96% | 56.46% | 60.08% | 56.88% | 42.26% | 35.28% |
| Research & Development | 272.45K | 232.92K | 327.73K | 483.89K | 658.48K | 496.93K | 389.81K | 384.93K | 506.42K | 360.45K | 216.67K |
| General & Administrative | 0.00 | 0.00 | 352.50K | 672.12K | 791.04K | 879.56K | 1.15M | 1.48M | 1.37M | 1.07M | 1.19M |
| Selling & Marketing | 0.00 | 0.00 | 251.49K | 367.23K | 329.73K | 915.46K | 730.03K | 716.19K | 1.07M | 988.93K | 699.19K |
| SG&A | 468.23K | 597.05K | 622.26K | 1.07M | 1.20M | 1.89M | 1.97M | 2.27M | 2.61M | 2.07M | 1.90M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 740.68K | 829.97K | 949.98K | 1.55M | 1.86M | 2.39M | 2.36M | 2.66M | 3.12M | 2.62M | 2.04M |
| Cost & Expenses | 989.00K | 1.05M | 1.76M | 1.88M | 2.27M | 3.08M | 3.12M | 3.49M | 4.13M | 3.36M | 2.47M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 603.96K | 637.17K |
| Interest Expense | 448.52K | 441.46K | 314.58K | 263.57K | 994.06K | 952.70K | 758.54K | 711.29K | 667.19K | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | 228.49K | 137.13K | 829.00 | 829.00 | 2.21K | 2.21K | 3.22K | 10.96K | 16.68K | 16.56K |
| EBITDA | -274.29K | -343.45K | 24.76K | -1.05M | -1.31M | -2.01M | -1.29M | -1.35M | -1.64M | -1.88M | -1.88M |
| EBITDA Ratio | -38.38% | -48.55% | -9.60% | -126.26% | -141.27% | -194.43% | -77.00% | -66.85% | -75.89% | -145.98% | -282.53% |
| Operating Income | -274.29K | -343.45K | -154.45K | -1.05M | -1.33M | -2.04M | -1.36M | -1.40M | -1.79M | -1.90M | -1.90M |
| Operating Income Ratio | -38.38% | -48.55% | -9.60% | -126.26% | -141.35% | -194.64% | -77.12% | -67.01% | -76.36% | -147.28% | -285.02% |
| Total Other Income/Expenses | -448.52K | -441.46K | -135.37K | -112.29K | -994.06K | -952.70K | -758.54K | -706.52K | -663.79K | -603.96K | -548.79K |
| Income Before Tax | -722.81K | -784.91K | -289.82K | -1.16M | -2.33M | -2.99M | -2.12M | -2.11M | -2.45M | -2.68M | -2.45M |
| Income Before Tax Ratio | -101.13% | -110.96% | -18.01% | -139.80% | -246.91% | -285.73% | -120.13% | -100.81% | -104.73% | -207.56% | -367.48% |
| Income Tax Expense | -167.90K | -228.49K | -137.13 | 0.17 | 2.00 | -3.00 | 3.00 | 4.00 | 2.00 | 0.00 | 0.00 |
| Net Income | -722.81K | -784.91K | -289.82K | -1.16M | -2.33M | -2.99M | -2.12M | -2.11M | -2.45M | -2.68M | -2.45M |
| Net Income Ratio | -101.13% | -110.96% | -18.01% | -139.80% | -246.91% | -285.73% | -120.13% | -100.81% | -104.73% | -207.56% | -367.48% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 24.71B | 24.54B | 24.26B | 23.53B | 21.81B | 19.85B | 16.98B | 12.84B | 8.56B | 4.46B | 3.27B |
| Weighted Avg Shares Out (Dil) | 24.71B | 24.54B | 24.26B | 23.53B | 21.81B | 19.85B | 16.98B | 12.84B | 8.56B | 4.84B | 3.26B |
Sree Koneru, PhD Joins the Board of Directors of BioElectronics Corporation
FREDERICK, Md., Dec. 03, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL, a developer of medical technology products, today announces that Sree Koneru, PhD, will join its Board of Directors, effective December 3, 2024. Upon Dr. Koneru's appointment, the...
BioElectronics Corporation's Chairman Updates Investors
Outlines Sales Activities, Clinical Trials, and a Potential Legal Action Against MundiPharma FREDERICK, Md., Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard Staelin,...
BioElectronics Corporation Announces the Publication of a Canine Arthritis Study
96% of the Dogs Treated With the Active Model 088 Device Showed Marked Improvement FREDERICK, MD, March 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- BioElectronics Corporation ( https://www.bielcorp.com/ OTC: BIEL) a developer of medical technology products, announces the results...
BioElectronics Corporation Announces the Publication of Pilot Study Results
Beneficial Treatment Effect for Phantom and Residual Limb Pain Identified FREDERICK, MD, Feb. 23, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today announces the publication of a study investigating...
BioElectronics Chairman Updates Investors
Discusses Clinical Trial Progress and Potential Legal Action Against MundiPharma FREDERICK, MD, Feb. 15, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corporation (https://www.bielcorp.com/ OTC: BIEL a developer of medical technology products, today releases an update from its Chairman, Richard...
End of Year Message From the Chairman of the Board of BioElectronics
FREDERICK, MD, Dec. 22, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioElectronics Corp. (OTC: BIEL) is pleased to provide this end of year message to investors, customers, suppliers and other partners. As described below, the last six months have produced...
Source: https://incomestatements.info
Category: Stock Reports